Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb 23;10(3):499.
doi: 10.3390/microorganisms10030499.

SARS-CoV-2-Legionella Co-Infections: A Systematic Review and Meta-Analysis (2020-2021)

Matteo Riccò  1 , Pietro Ferraro  2 , Simona Peruzzi  3 , Alessandro Zaniboni  4 , Silvia Ranzieri  4
Affiliations
Review

SARS-CoV-2-Legionella Co-Infections: A Systematic Review and Meta-Analysis (2020-2021)

Matteo Riccò et al. Microorganisms. .

Abstract

Legionnaires' Disease (LD) is a severe, sometimes fatal interstitial pneumonia due to Legionella pneumophila. Since the inception of the SARS-CoV-2 pandemic, some contradictory reports about the effects of lockdown measures on its epidemiology have been published, but no summary evidence has been collected to date. Therefore, we searched two different databases (PubMed and EMBASE) focusing on studies that reported the occurrence of LD among SARS-CoV-2 cases. Data were extracted using a standardized assessment form, and the results of such analyses were systematically reported, summarized, and compared. We identified a total of 38 articles, including 27 observational studies (either prospective or retrospective ones), 10 case reports, and 1 case series. Overall, data on 10,936 SARS-CoV-2 cases were included in the analyses. Of them, 5035 (46.0%) were tested for Legionella either through urinary antigen test or PCR, with 18 positive cases (0.4%). A pooled prevalence of 0.288% (95% Confidence Interval (95% CI) 0.129-0.641), was eventually calculated. Moreover, detailed data on 19 co-infections LD + SARS-CoV-2 were obtained (males: 84.2%; mean age: 61.9 years, range 35 to 83; 78.9% with 1 or more underlying comorbidities), including 16 (84.2%) admissions to the ICU, with a Case Fatality Ratio of 26.3%. In summary, our analyses suggest that the occurrence of SARS-CoV-2-Legionella infections may represent a relatively rare but not irrelevant event, and incident cases are characterized by a dismal prognosis.

Keywords: COVID-19; Legionella pneumophila typing; Legionnaires’ disease; SARS-CoV-2; diagnosis; epidemiology.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure A1
Figure A1
Forest plot representing the estimated case fatality ratio (CFR) among individuals affected by SARS-CoV-2 in the retrieved studies. Pooled CFR was estimated in 12.820% (95% Confidence Interval (95% CI) 7.199–21.801), with estimates that were considerably greater in PCR-based studies (14.688%, 95% CI 5.765–32.636) compared to those based on LUAT (11.571%, 95% CI 5.573–22.487) (note: Pos. = deaths; Tot. = total cases; Prev. = Estimated CFR).
Figure A2
Figure A2
Border-enhanced funnel plot for studies included in the meta-analysis (a), and the corresponding radial plot (b). Visual inspection of the contour-enhanced funnel plot suggested substantial evidence of publication bias, but this was substantially ruled out by the Egger test (i.e., t = −1.05, df = 12, p-value = 0.3131). On the other hand, in radial plots, the studies were substantially scattered across the regression line, suggesting no significant small study effect.
Figure 1
Figure 1
PRISMA flowchart for retrieved studies.
Figure 2
Figure 2
Forest plot representing the estimated pooled prevalence (Prev.) for Legionella infection (Pos.) among individuals affected by SARS-CoV-2 (Tot.). The pooled prevalence rate was estimated at 0.288% (95% Confidence Interval (95% CI) 0.129–0.641), with estimates that were considerably greater in PCR-based studies (0.377%, 95% CI 0.118–1.194) compared to those based on LUAT (0.247%, 95% CI 0.078–0.777).
Figure 3
Figure 3
Border-enhanced funnel plot for studies included in the meta-analysis (a), and the corresponding radial plot (b). Visual inspection of the contour-enhanced funnel plot suggested substantial evidence of publication bias, and this was substantially excluded by the Egger test (i.e., t = −1.25, df = 25, p-value = 0.2235). In fact, in radial plots, the studies on were substantially scattered across the regression line, suggesting no significant small study effect.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Flaxman S., Mishra S., Gandy A., Unwin H.J.T., Mellan T.A., Coupland H., Whittaker C., Zhu H., Berah T., Eaton J.W., et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature. 2020;584:257–261. doi: 10.1038/s41586-020-2405-7. - DOI - PubMed
    1. Ullrich A., Schranz M., Rexroth U., Hamouda O., Schaade L., Diercke M., Boender T.S. Impact of the COVID-19 pandemic and associated non-pharmaceutical interventions on other notifiable infectious diseases in Germany: An analysis of National Surveillance Data during Week 1—2016–Week 32—2020. Lancet Reg. Health—Eur. 2021;6:100103. doi: 10.1016/j.lanepe.2021.100103. - DOI - PMC - PubMed
    1. Oh D.-Y., Buda S., Biere B., Reiche J., Schlosser F., Duwe S., Wedde M., von Kleist M., Mielke M., Wolff T., et al. Trends in respiratory virus circulation following COVID-19-targeted nonpharmaceutical interventions in Germany, January–September 2020: Analysis of National Surveillance Data. Lancet Reg. Health—Eur. 2021;6:100112. doi: 10.1016/j.lanepe.2021.100112. - DOI - PMC - PubMed
    1. Müller O., Razum O., Jahn A. Effects of non-pharmaceutical interventions against COVID-19 on the incidence of other diseases. Lancet Reg. Health—Eur. 2021;6:100139. doi: 10.1016/j.lanepe.2021.100139. - DOI - PMC - PubMed
    1. Hall C.B., Weinberg G.A., Iwane M.K., Blumkin A.K., Edwards K.M., Staat M.A., Auinger P., Griffin M.R., Poehling K.A., Erdman D., et al. The burden of respiratory syncytial virus infection in young children. N. Engl. J. Med. 2009;360:588–598. doi: 10.1056/NEJMoa0804877. - DOI - PMC - PubMed